The University of Chicago Header Logo

Connection

Hedy Kindler to Pancreatic Neoplasms

Back to Details
This is a "connection" page, showing publications Hedy Kindler has written about Pancreatic Neoplasms.
Hedy Kindler
Connection Strength
9.947
Pancreatic Neoplasms
  1. Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Cancer. 2023 05 01; 129(9):1411-1418.
    View in: PubMed
    Score: 0.603
  2. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022 12 01; 40(34):3929-3939.
    View in: PubMed
    Score: 0.578
  3. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 12 01; 30(12):1959-1968.
    View in: PubMed
    Score: 0.482
  4. Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2019 10 10; 381(15):1492-1493.
    View in: PubMed
    Score: 0.477
  5. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 07 25; 381(4):317-327.
    View in: PubMed
    Score: 0.466
  6. A Glimmer of Hope for Pancreatic Cancer. N Engl J Med. 2018 12 20; 379(25):2463-2464.
    View in: PubMed
    Score: 0.451
  7. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
    View in: PubMed
    Score: 0.416
  8. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
    View in: PubMed
    Score: 0.363
  9. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. Am Soc Clin Oncol Educ Book. 2014; e157-64.
    View in: PubMed
    Score: 0.320
  10. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 2012 Nov; 23(11):2834-2842.
    View in: PubMed
    Score: 0.287
  11. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011 Mar; 12(3):256-62.
    View in: PubMed
    Score: 0.263
  12. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs. 2012 Feb; 30(1):382-6.
    View in: PubMed
    Score: 0.254
  13. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 2008 Dec; 31(6):553-6.
    View in: PubMed
    Score: 0.225
  14. Pancreatic cancer: an update. Curr Oncol Rep. 2007 May; 9(3):170-6.
    View in: PubMed
    Score: 0.202
  15. Front-line therapy of advanced pancreatic cancer. Semin Oncol. 2005 Dec; 32(6 Suppl 9):S33-6.
    View in: PubMed
    Score: 0.183
  16. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.182
  17. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs. 2005 Oct; 23(5):489-93.
    View in: PubMed
    Score: 0.181
  18. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005 Oct; 16(10):1639-45.
    View in: PubMed
    Score: 0.179
  19. Chemotherapy for advanced pancreatic cancer: past, present, and future. Curr Oncol Rep. 2005 May; 7(3):186-95.
    View in: PubMed
    Score: 0.175
  20. In focus: advanced pancreatic cancer. Clin Adv Hematol Oncol. 2005 May; 3(5):420-2.
    View in: PubMed
    Score: 0.175
  21. A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 11 01; 30(11).
    View in: PubMed
    Score: 0.157
  22. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Oncologist. 2023 07 05; 28(7):584-595.
    View in: PubMed
    Score: 0.155
  23. Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma. JCO Precis Oncol. 2023 01; 7:e2200196.
    View in: PubMed
    Score: 0.149
  24. Pemetrexed in pancreatic cancer. Semin Oncol. 2002 Dec; 29(6 Suppl 18):49-53.
    View in: PubMed
    Score: 0.148
  25. The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer. 2002 Aug 15; 95(4 Suppl):928-32.
    View in: PubMed
    Score: 0.145
  26. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. J Clin Oncol. 2020 05 01; 38(13):1442-1454.
    View in: PubMed
    Score: 0.122
  27. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020 05 01; 38(13):1378-1388.
    View in: PubMed
    Score: 0.122
  28. Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
    View in: PubMed
    Score: 0.118
  29. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenet Genomics. 2019 08; 29(6):123-131.
    View in: PubMed
    Score: 0.118
  30. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502.
    View in: PubMed
    Score: 0.116
  31. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer. 2019 05 15; 125(10):1629-1636.
    View in: PubMed
    Score: 0.113
  32. Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Mol Cancer Res. 2019 01; 17(1):70-83.
    View in: PubMed
    Score: 0.111
  33. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
    View in: PubMed
    Score: 0.110
  34. The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. J Geriatr Oncol. 2018 07; 9(4):367-372.
    View in: PubMed
    Score: 0.107
  35. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
    View in: PubMed
    Score: 0.107
  36. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018 04 01; 124(7):1374-1382.
    View in: PubMed
    Score: 0.106
  37. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018 01; 89:19-26.
    View in: PubMed
    Score: 0.105
  38. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer. 2017 Mar 14; 116(6):697-702.
    View in: PubMed
    Score: 0.099
  39. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
    View in: PubMed
    Score: 0.096
  40. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5.
    View in: PubMed
    Score: 0.093
  41. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2015 May 10; 33(14):1551-6.
    View in: PubMed
    Score: 0.085
  42. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
    View in: PubMed
    Score: 0.085
  43. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). J Natl Cancer Inst. 2014 Aug; 106(8).
    View in: PubMed
    Score: 0.083
  44. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66.
    View in: PubMed
    Score: 0.079
  45. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res. 2013 Aug 01; 19(15):4282-9.
    View in: PubMed
    Score: 0.077
  46. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug; 20(8):2787-95.
    View in: PubMed
    Score: 0.075
  47. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer. Qual Life Res. 2013 Jun; 22(5):1105-12.
    View in: PubMed
    Score: 0.072
  48. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84.
    View in: PubMed
    Score: 0.069
  49. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012 Feb; 43(2):205-17.
    View in: PubMed
    Score: 0.069
  50. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer. 2012 Jan 15; 118(2):571-8.
    View in: PubMed
    Score: 0.067
  51. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9.
    View in: PubMed
    Score: 0.065
  52. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22.
    View in: PubMed
    Score: 0.063
  53. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.
    View in: PubMed
    Score: 0.060
  54. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007 Sep 01; 13(17):5144-9.
    View in: PubMed
    Score: 0.052
  55. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6111-8.
    View in: PubMed
    Score: 0.042
  56. Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol. 2002 Apr; 29(2 Suppl 5):42-9.
    View in: PubMed
    Score: 0.035
  57. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.